Hepatitis C virus non-structural NS3/4A fusion gene
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/29
A61L-002/00
출원번호
US-0249893
(2005-10-13)
등록번호
US-7439347
(2008-10-21)
발명자
/ 주소
S��llberg,Matti
출원인 / 주소
Tripep AB
대리인 / 주소
Knobbe Martens Olson & Bear LLP
인용정보
피인용 횟수 :
4인용 특허 :
85
초록▼
Disclosed herein is the discovery of a novel hepatitis C virus (HCV) isolated from a human patient. Embodiments of the invention include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as,
Disclosed herein is the discovery of a novel hepatitis C virus (HCV) isolated from a human patient. Embodiments of the invention include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as, methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.
대표청구항▼
What is claimed is: 1. A composition comprising a purified or isolated nucleic acid that comprises at least 100 consecutive nucleotides of SEQ. ID. No. 1 or the complement thereof, wherein said at least 100 consecutive nucleotide encodes a polypeptide comprising a NS3 domain of a fragment thereof.
What is claimed is: 1. A composition comprising a purified or isolated nucleic acid that comprises at least 100 consecutive nucleotides of SEQ. ID. No. 1 or the complement thereof, wherein said at least 100 consecutive nucleotide encodes a polypeptide comprising a NS3 domain of a fragment thereof. 2. The composition of claim 1, wherein said nucleic acid comprises at least 200 consecutive nucleotides of SEQ. ID. No. 1. 3. The composition of claim 1, wherein said nucleic acid comprises at least 500 consecutive nucleotides of SEQ. ID. No. 1. 4. The composition of claim 1, wherein said nucleic acid comprises at least 1000 consecutive nucleotides of SEQ. ID. No. 1. 5. The composition of claim 1, wherein said nucleic acid comprises a mutation that inhibits proteolytic cleavage of NS3 and NS4A. 6. The composition of claim 2, wherein said nucleic acid comprises a mutation that inhibits proteolytic cleavage of NS3 and NS4A. 7. The composition of claim 3, wherein said nucleic acid comprises a mutation that inhibits proteolytic cleavage of NS3 and NS4A. 8. The composition of claim 4, wherein said nucleic acid comprises a mutation that inhibits proteolytic cleavage of NS3 and NS4A. 9. The composition of claim 1, wherein said nucleic acid encodes a polypeptide lacking a proteolytic cleavage site that inhibits proteolytic cleavage of NS3 and NS4A. 10. The composition of claim 1, comprising a vector that comprises said nucleic acid. 11. The composition of claim 2, comprising a vector that comprises said nucleic acid. 12. The composition of claim 3, comprising a vector that comprises said nucleic acid. 13. The composition of claim 4, comprising a vector that comprises said nucleic acid. 14. The composition of claim 5, comprising a vector that comprises said nucleic acid. 15. The composition of claim 6, comprising a vector that comprises said nucleic acid. 16. The composition of claim 7, comprising a vector that comprises said nucleic acid. 17. The composition of claim 8, comprising a vector that comprises said nucleic acid. 18. The composition of claim 9, comprising a vector that comprises said nucleic acid. 19. The composition of claim 1, further comprising an adjuvant. 20. The composition of claim 2, further comprising an adjuvant. 21. The composition of claim 3, further comprising an adjuvant. 22. The composition of claim 4, further comprising an adjuvant. 23. The composition of claim 5, further comprising an adjuvant. 24. The composition of claim 6, further comprising an adjuvant. 25. The composition of claim 7, further comprising an adjuvant. 26. The composition of claim 8, further comprising an adjuvant. 27. The composition of claim 9, further comprising an adjuvant. 28. The composition of claim 1, further comprising ribavirin. 29. The composition of claim 2, further comprising ribavirin. 30. The composition of claim 3, further comprising ribavirin. 31. The composition of claim 4, further comprising ribavirin. 32. The composition of claim 5, further comprising ribavirin. 33. The composition of claim 6, further comprising ribavirin. 34. The composition of claim 7, further comprising ribavirin. 35. The composition of claim 8, further comprising ribavirin. 36. The composition of claim 9, further comprising ribavirin. 37. The composition of claim 1, wherein said composition is formulated for use with an electroporation device. 38. The composition of claim 1, wherein said composition is formulated for use with an injection device. 39. The composition of claim 38, wherein said injection device is a needleless injection device. 40. The composition of claim 2, wherein said composition is formulated for use with an electroporation device. 41. The composition of claim 2, wherein said composition is formulated for use with an injection device. 42. The composition of claim 41, wherein said injection device is a needleless injection device. 43. The composition of claim 3, wherein said composition is formulated for use with an electroporation device. 44. The composition of claim 3, wherein said composition is formulated for use with an injection device. 45. The composition of claim 44, wherein said injection device is a needleless injection device. 46. The composition of claim 4, wherein said composition is formulated for use with an electroporation device. 47. The composition of claim 4, wherein said composition is formulated for use with an injection device. 48. The composition of claim 47, wherein said injection device is a needleless injection device. 49. The composition of claim 5, wherein said composition is formulated for use with an electroporation device. 50. The composition of claim 5, wherein said composition is formulated for use with an injection device. 51. The composition of claim 50, wherein said injection device is a needleless injection device. 52. The composition of claim 6, wherein said composition is formulated for use with an electroporation device. 53. The composition of claim 6, wherein said composition is formulated for use with an injection device. 54. The composition of claim 53, wherein said injection device is a needleless injection device. 55. The composition of claim 7, wherein said composition is formulated for use with an electroporation device. 56. The composition of claim 7, wherein said composition is formulated for use with an injection device. 57. The composition of claim 56, wherein said injection device is a needleless injection device. 58. The composition of claim 8, wherein said composition is formulated for use with an electroporation device. 59. The composition of claim 8, wherein said composition is formulated for use with an injection device. 60. The composition of claim 59, wherein said injection device is a needleless injection device. 61. The composition of claim 9, wherein said composition is formulated for use with an electroporation device. 62. The composition of claim 9, wherein said composition is formulated for use with an injection device. 63. The composition of claim 62, wherein said injection device is a needleless injection device. 64. A composition comprising a purified or isolated nucleic acid that comprises at least 100 consecutive nucleotides encoding a peptide sequence of SEQ. ID. NO: 2. 65. The composition of claim 1, wherein said nucleic acid comprises at least 500 consecutive nucleotides encoding the peptide sequence of SEQ. ID. NO: 2. 66. The composition of claim 64, further comprising an adjuvant. 67. The composition of claim 64, further comprising ribavirin. 68. The composition of claim 64, wherein said composition is formulated for use with an electroporation device. 69. The composition of claim 64, wherein said composition is formulated for use with an injection device. 70. The composition of claim 69, wherein said injection device is a needleless injection device.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (85)
Ralston,Robert O.; Marcus,Frank; Thudium,Kent B.; Gervase,Barbara A.; Hall,John A.; Berger,Kim M.; Choo,Qui Lim; Houghton,Michael; Kuo,George, Antibodies to hepatitis C virus asialoglycoproteins.
Houghton Michael (Danville CA) Choo Qui-Lim (El Cerrito CA) Kuo George (San Francisco CA), Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies.
Ralston Robert O. ; Marcus Frank ; Thudium Kent B. ; Gervase Barbara A. ; Hall John A. ; Berger Kim M. ; Choo Oui-Lim ; Houghton Michael ; Kuo George, Hepatitis C virus asialoglycoproteins.
Ralston Robert O. ; Marcus Frank ; Thudium Kent B. ; Gervase Barbara A. ; Hall John A. ; Berger Kim M. ; Choo Qui-Lim ; Houghton Michael ; Kuo George, Hepatitis C virus asialoglycoproteins.
Ralston Robert O. ; Marcus Frank ; Thudium Kent B. ; Gervase Barbara A. ; Hall John A. ; Berger Kim M. ; Choo Qui-Lim ; Houghton Michael ; Kuo George, Hepatitis C virus asialoglycoproteins.
Ralston Robert O. ; Marcus Frank ; Thudium Kent B. ; Gervase Barbara A. ; Hall John A. ; Berger Kim M. ; Choo Qui-Lim ; Houghton Michael ; Kuo George, Hepatitis C virus asialoglycoproteins.
Miyamura Tatsuo,JPX ; Saito Izumi,JPX ; Houghton Michael ; Weiner Amy J. ; Han Jang ; Kolberg Janice A. ; Cha Tai-An ; Irvine Bruce D., Hepatitis C virus isolate polypeptides.
Miyamura Tatsuo (Tokyo JPX) Saito Izumi (Tokyo CA JPX) Houghton Michael (Danville CA) Weiner Amy J. (Benicia CA) Han Jang (Lafayette CA) Kolberg Janice A. (Hercules CA) Cha Tai-An (San Ramon CA) Irvi, Hepatitis C virus isolates.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Induction of a protective immune response in a mammal by injecting a DNA sequence.
Pirrung Michael C. (Durham NC) Read J. Leighton (Palo Alto CA) Fodor Stephen P. A. (Palo Alto CA) Stryer Lubert (Stanford CA), Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof.
Houghton Michael ; Choo Qui-Lim ; Kuo George ; Weiner Amy J. ; Han Jang ; Urdea Michael Steven ; Irvine Bruce Duncan ; Kolberg Janice A., Methods for detecting Hepatitis C virus using polynucleotides specific for same.
Houghton Michael ; Choo Qui-Lim ; Kuo George ; Weiner Amy J. ; Han Jang ; Urdea Michael Steven ; Irvine Bruce Duncan ; Kolberg Janice A., NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus.
Brechot Christian,FRX ; Kremsdorf Dina,FRX ; Porchon Colette,FRX, Nucleotide and peptide sequences of a hepatitis C virus isolate, diagnostic and therapeutic applications.
Mullis Kary B. (La Jolla CA) Erlich Henry A. (Oakland CA) Gelfand David H. (Oakland CA) Horn Glenn (Emeryville CA) Saiki Randall K. (Richmond CA), Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme.
Mullis Kary B. (Kensington CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or-cloning nucleic acid sequences.
McGall Glenn H. (Mountain View CA) Fodor Stephen P. A. (Palo Alto CA) Sheldon Edward L. (Menlo Park CA), Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.